Luigi Colecchia

Dr. Luigi Colecchia

DIMEC, University of Bologna, Bologna, Emilia-Romagna, Italy
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2023 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Closed access
EDElton Dajti
Elton Dajti
FRFederico Ravaioli
Federico Ravaioli
RZRomanas Zykus
Romanas Zykus
PRPierre-Emmanuel Rautou
Pierre-Emmanuel Rautou
LELaure Elkrief
Laure Elkrief
DRDante Romagnoli
Dante Romagnoli

21 July 2022 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
EDElton Dajti
Elton Dajti
FRFederico Ravaioli
Federico Ravaioli
Giovanni MarascoGiovanni Marasco
Giovanni Marasco
LALuigina Vanessa Alemanni
Luigina Vanessa Alemanni
LCLuigi Colecchia
Luigi Colecchia
ACAntonio Colecchia
Antonio Colecchia
INTRODUCTION: A noninvasive diagnosis of clinically significant portal hypertension (CSPH) has important prognostic and therapeutic implications for patients with compensated advanced chronic liver disease. We aimed to validate and improve the available algorithms for the CSPH diagnosis by evaluating spleen stiffness measurement (SSM) in patients with compensated advanced chronic liver disease. METHODS: This is a retrospective study including patients with liver stiffness measurement (LSM) ≥10 kPa, no previous decompensation, and available measurements of hepatic venous pressure gradient, LSM, and SSM by transient elastography referring to our center in Bologna. The diagnostic algorithms were adequate if negative and positive predictive values were >90% when ruling out and ruling in CSPH, respectively; these models were validated in a cohort from Verona. The 5-year decompensation rate was reported. RESULTS: One hundred fourteen patients were included in the derivation cohort. The Baveno VII diagnostic algorithm (LSM ≤15 kPa + platelet count ≥150 × 109/L to rule out CSPH and LSM >25 kPa to rule in CSPH) was validated; however, 40%–60% of the patients remained in the gray zone. The addition of SSM (40 kPa) to the model significantly reduced the gray zone to 7%–15%, maintaining adequate negative and positive predictive values. The diagnostic algorithms were validated in a cohort of 81 patients from Verona. All first decompensation events occurred in the “rule-in” zone of the model including SSM. DISCUSSION: The addition of SSM significantly improves the clinical applicability of the algorithm based on LSM and platelet count for CSPH diagnosis. Our models can be used to noninvasively identify candidates for nonselective beta-blocker treatment and patients at a high risk of decompensation.

23 September 2024 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Closed access
MJMathias Jachs
Mathias Jachs
AOAitor Odriozola
Aitor Odriozola
FTFanny Turon
Fanny Turon
LMLucile Moga
Lucile Moga
LTLuis Téllez
Luis Téllez
HGHelena Greenfield
Helena Greenfield

14 July 2020 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
ABAnna Rita Di Biase
Anna Rita Di Biase
Giovanni MarascoGiovanni Marasco
Giovanni Marasco
FRFederico Ravaioli
Federico Ravaioli
EDElton Dajti
Elton Dajti
LCLuigi Colecchia
Luigi Colecchia
ACAntonio Colecchia
Antonio Colecchia

15 June 2020 in Hepatology International
Verified
Journal Article
Closed access
PDF file
Giovanni MarascoGiovanni Marasco
Giovanni Marasco
EDElton Dajti
Elton Dajti
Federico RavaioliFederico Ravaioli
Federico Ravaioli
LALuigina Vanessa Alemanni
Luigina Vanessa Alemanni
FCFabiana Capuano
Fabiana Capuano
ACAntonio Colecchia
Antonio Colecchia

28 June 2020 in World Journal of Gastroenterology
Verified
Journal Article
Open access
Giovanni MarascoGiovanni Marasco
Giovanni Marasco
ACAntonio Colecchia
Antonio Colecchia
GSGiovanni Silva
Giovanni Silva
BRBenedetta Rossini
Benedetta Rossini
LELeonardo Henry Eusebi
Leonardo Henry Eusebi
DFDavide Festi
Davide Festi
Non-invasive tests for the prediction of primary hepatocellular carcinoma